Genmab A (GMAB) EBT Margin (2018 - 2026)
Genmab A's (GMAB) quarterly EBT Margin came in at 25.54% in Q2 2026, down 1513.0% on a YoY basis from 1.81% in Q2 2025, and up 209.25% quarter-over-quarter from 8.26% in Q1 2026.
Powered by 
Analysis
Genmab A (GMAB) EBT Margin (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has reported EBT Margin for 9 consecutive years, with 25.54% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 1513.0% year-over-year to 25.54%; the trailing twelve-month figure through Jun 2026 stood at 34.39% (down 396.0% YoY), and the FY2025 full-year result was 32.37%, down 1012.0% from the prior year.
- EBT Margin improved to 25.54% in Q2 2026 per GMAB's latest filing, from 8.26% in the prior quarter.
- Across five years, EBT Margin topped out at 78.72% in Q2 2022 and bottomed at 8.26% in Q1 2026.
- Historically, EBT Margin has averaged 40.57% across 5 years, with a median of 40.54% in 2023.
- The sharpest annual moves came in 2022 and 2026: EBT Margin soared 651 bps in 2022, then tumbled 2587 bps in 2026.
- Over 5 years, EBT Margin stood at 78.72% in 2022, then sank by 49 bps to 40.54% in 2023, then decreased by 9 bps to 36.81% in 2024, then increased by 17 bps to 43.16% in 2025, then tumbled by 41 bps to 25.54% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 25.54%, 8.26%, and 43.16% for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 35.61% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -528.97% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 35.78% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -20,427.46% |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 25.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.54% |
| Mar 31, 2026 | 8.26% |
| Sep 30, 2025 | 43.16% |
| Jun 30, 2025 | 40.67% |
| Mar 31, 2025 | 34.13% |
| Sep 30, 2024 | 36.81% |
| Jun 30, 2024 | 40.23% |
| Mar 31, 2024 | 41.29% |
| Dec 31, 2023 | 40.54% |
| Sep 30, 2023 | 56.96% |
| Jun 30, 2022 | 78.72% |
| Dec 31, 2021 | 21.40% |
| Sep 30, 2021 | 50.69% |
| Jun 30, 2021 | 72.21% |
| Dec 31, 2020 | 79.40% |
| Sep 30, 2020 | 38.92% |
| Jun 30, 2020 | 79.40% |
| Dec 31, 2019 | 67.21% |
| Sep 30, 2019 | 67.25% |
| Jun 30, 2019 | 14.34% |